

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter 1, Parts 30, 31, 32, 33, 34, 35, 36, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s); and to import such byproduct and source material. This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee		
1. St. Mary's Hospital		3. License number 29-20597-01
2. 135 Center Street Orange, New Jersey 07051		4. Expiration date May 31, 1988
		5. Docket or Reference No. 030-19962
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A.
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form, except generators, listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. As necessary for uses authorized in Subitem 9.B.
C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. As necessary for uses authorized in Subitem 9.C.
D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. Any radiopharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. As necessary for uses authorized in Subitem 9.D.
E. Any byproduct material listed in Section 31.11(a) of 10 CFR 31	E. Any	E. 3 millicuries of each byproduct material authorized in Subitem 6.E.

B-1

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

29-20597-01

Docket or Reference number

030-19962

(12. continued)

CONDITIONS

Arnold I. Brenner, D.O.

Groups I, II, and III

In vitro studies

Xenon 133

Iodine 131 as iodide for treatment of hyperthyroidism, cardiac dysfunction, and thyroid carcinoma

Phosphorus 32 as soluble phosphate for treatment of polycythemia vera, leukemia, and bone metastases

13. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.
14. Patients containing Iodine 131 for the treatment of thyroid carcinoma or patients containing therapeutic quantities of Gold 198 shall remain hospitalized until the residual activity is 30 millicuries or less.
15. For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:
- (a) Has the prior written permission of the hospital's Administrator and its Medical Isotopes Committee, and
 - (b) Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and
 - (c) Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

The licensee shall maintain for the inspection by the Commission copies of the written permission specified in subitem (a) above and of the license(s) specified in subitems (b) and (c) above. These records shall be maintained for five (5) years from the time the licensee grants its permission under subitem (a) above.

16. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:
- A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of ten (10) half-lives.
 - B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.


MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number	29-20597-01
Docket or Reference number	030-19962

(continued)

CONDITIONS

17. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated March 28, 1983; letters dated May 3, 1983, and May 4, 1983; and Model ALARA Program contained in Appendix O of Regulatory Guide 10.8 (Rev. 1), "Guide for the Preparation of Applications for Medical Programs", October 1980. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.



For the U.S. Nuclear Regulatory Commission

Original Signed By:
Phillip C. Jerman

By

Nuclear Materials and Safeguards Branch
Region I
King of Prussia, Pennsylvania 19406

Date

MAY 18 1983